GlassScriptPhysician profile
Nam D Vo
NPI 1255382214
$89,072.35
in general payments reported to CMS, 2019-2025
17 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,816 · 2022: $22K · 2023: $6,063 · 2024: $31K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $5,509 · Travel and Lodging: $4,088 · Food and Beverage: $2,974 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,600 · Education: $55.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,816.00 |
| Consulting Fee | $5,509.09 |
| Travel and Lodging | $4,087.91 |
| Food and Beverage | $2,973.65 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,600.00 |
| Education | $55.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27,798.00 | 2021-2024 | |
| Lilly USA, LLC | $25,377.75 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,713.91 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $13,698.09 | 2021-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $7,418.44 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $279.03 | 2022-2024 | Ultomiris |
| Abbott Laboratories | $194.33 | 2024 | Eterna |
| Medtronic, INC. | $150.96 | 2025 | Symplicity G3 |
| Amgen INC. | $146.96 | 2022-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Baxter Healthcare | $65.71 | 2023 | |
| Becton, Dickinson and Company | $39.00 | 2023 | |
| Vifor Pharma, INC. | $37.77 | 2022-2024 | Veltassa |
| Nxstage Medical, INC. | $27.40 | 2023 | Nxstage System One |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nam Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.